参考文献/References:
[1] Mudd JO,Borlaug BA,Johnston PV,et al. Beyond low-density lipoprotein cholesterol:defining the role of low-density lipoprotein heterogeneity in coronary artery disease[J]. J Am Coll Cardiol ,2007,50(18):1735-1741.
[2] Christopher PC,Michael AB,Rober P G,et al. Ezetimibe added to Statin Therapy after acute coronary syndromes[J].N Eng J Med ,2015,372(25):2387-2397.
[3] Varbo A,Nordestgaard BG. Remnant lipoproteins[J]. Curr Opin Lipidol ,2017,28(4):300-307.
[4] Martin SS,Blaha MJ,Elshazly MB,et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications[J]. J Am Coll Cardiol,2013,62(8):732-739.
[5] Jepsen AM,Langsted A,Varbo A,et al. Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease[J]. Clin Chem ,2016,62(4):593-604.
[6] Lupton JR,Faridi KF,Martin SS,et al. Deficient serum 25-hydroxyvitamin D is associated with an atherogenic lipid profile:the very large database of lipids (VLDL-3) study[J]. J Clin Lipidol ,2016,10(1):72-81.
[7] Varbo A,Nordestgaard BG. Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction[J]. Eur Heart J ,2021,42(47):4833-4843.
[8] Chan DC,Pang J,Romic G,et al. Postprandial hypertriglyceridemia and cardiovascular disease:current and future therapies[J]. Curr Atheroscler Rep ,2013,15(3):309.
[9] Xiang QY,Tian F,Lin QZ,et al. Comparison of remnant cholesterol levels estimated by calculated and measured LDL-C levels in Chinese patients with coronary heart disease[J]. Clin Chim Acta ,2020,500:75-80.
[10] Fujihara Y,Nakamura T,Horikoshi T,et al. Remnant lipoproteins are residual risk factor for future cardiovascular events in patients with stable coronary artery disease and on-statin low-density lipoprotein cholesterol levels<70 mg/dL[J]. Circ J ,2019,83(6):1302-1308.
[11] Joshi PH,Khokhar AA,Massaro JM,et al. Remnant lipoprotein cholesterol and incident coronary heart disease:the jackson heart and framingham offspring cohort studies [J]. J Am Heart Assoc ,2016,5(5):e002765.
[12] Ibarrola-Jurado N,Bulló M,Guasch-Ferré M,et al. Cross-sectional assessment of nut consumption and obesity, metabolic syndrome and other cardiometabolic risk factors:the PREDIMED study [J]. PLoS One ,2013,8(2):e57367.
[13] Estruch R,Ros E,Salas-Salvadó J,et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts[J]. N Engl J Med ,2018,378(25):e34.
[14] Quispe R,Martin SS,Michos ED,et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB:a primary prevention study[J]. Eur Heart J ,2021,42(42):4324-4332.
[15] Balling M,Afzal S,Varbo A,et al. VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins[J]. J Am Coll Cardiol,2020,76(23):2725-2735.
[16] Tada H,Kawashiri MA,Nohara A,et al. Remnant-like particles and coronary artery disease in familial hypercholesterolemia[J]. Clin Chim Acta ,2018,482:120-123.
[17] Zhao Q,Zhang TY,Cheng YJ,et al. Prognostic impact of estimated remnant-like particle cholesterol in patients with differing glycometabolic status:an observational cohort study from China[J]. Lipids Health Dis ,2020,19(1):179.
[18] Nguyen SV,Nakamura T,Uematsu M,et al. Remnant lipoproteinemia predicts cardiovascular events in patients with type 2 diabetes and chronic kidney disease [J]. J Cardiol ,2017,69(3):529-535.
[19] Nordestgaard BG,Varbo A. Triglycerides and cardiovascular disease[J]. Lancet ,2014,384(9943):626-635.
[20] Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease:new insights from epidemiology, genetics, and biology [J]. Circ Res ,2016,118(4):547-563.
[21] Sandesara PB,Virani SS,Fazio S,et al. The forgotten lipids:triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk[J]. Endocr Rev ,2019,40(2):537-557.
[22] Vallejo-Vaz AJ,Fayyad R,Boekholdt SM,et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial [J]. Circulation ,2018,138(8):770-781.
[23] Yuan G,Al-Shali KZ,Hegele RA. Hypertriglyceridemia:its etiology, effects and treatment [J]. CMAJ ,2007,176(8):1113-1120.
[24] Boden WE,Probstfield JL,Anderson T,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy[J]. N Engl J Med ,2011,365(24):2255-2267.
[25] Shapiro MD,Fazio S. From lipids to inflammation:new approaches to reducing atherosclerotic risk[J]. Circ Res ,2016,118(4):732-749.
[26] Witztum JL,Gaudet D,Freedman SD,et al. Volanesorsen and triglyceride levels?in familial chylomicronemia syndrome[J]. N Engl J Med ,2019,381(6):531-542.
[27] Gaudet D,Gipe DA,Pordy R,et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia[J]. N Engl J Med ,2017,377(3):296-297.
[28] Dewey FE,Gusarova V,Dunbar RL,et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease[J]. N Engl J Med ,2017,377(3):211-221.
相似文献/References:
[1]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(6):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[2]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(6):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[3]马晓磊 朱国斌.Wnt信号与动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展,2020,(8):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
MA Xiaolei,ZHU Guobin.Wnt Signaling and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(6):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
[4]黄毕.慢性肾脏病合并动脉粥样硬化性心血管疾病的调脂治疗进展[J].心血管病学进展,2020,(10):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
HUANG Bi.Lipid Management in Patients with Chronic Kidney Disease and Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(6):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
[5]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(6):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[6]蔡薇 杨堰焯 刘昊凌.甘油三酯葡萄糖乘积指数与糖尿病血管病变的研究进展[J].心血管病学进展,2022,(3):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
CAI Wei,YANG Yanzhuo,LIU Haoling.Triglyceride-Glucose Index and Diabetic Vascular Disease[J].Advances in Cardiovascular Diseases,2022,(6):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[7].胆固醇酯转移蛋白抑制剂在动脉粥样硬化性心血管疾病治疗中的研究进展[J].心血管病学进展,2022,(7):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
ZHU Jie,GAO Fen,XUE Shuanqin,et al.Treatment of Atherosclerotic Cardiovascular Diseases with Cholesteryl Ester Transfer Protein Inhibitor[J].Advances in Cardiovascular Diseases,2022,(6):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[8]欧阳运峰 李皇庆 李璐 阳军.脂蛋白a：动脉粥样硬化性心血管疾病防治新靶点[J].心血管病学进展,2022,(8):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]
OUYANG Yunfeng,LI Huangqing,LI Lu,et al.Lipoprotein A:a New Target for Prevention and Treatment of Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(6):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]
[9]安海英 涂建成.载脂蛋白B与非高密度脂蛋白胆固醇在ASCVD防控中的应用价值[J].心血管病学进展,2022,(9):803.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.009]
AN Haiying,TU Jiancheng.Application Value of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol in ASCVD Prevention and Control[J].Advances in Cardiovascular Diseases,2022,(6):803.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.009]
[10]徐笑挺,戴承晔,邓毅凡,等.二十碳五烯酸在动脉粥样硬化性心血管疾病中的研究进展[J].心血管病学进展,2022,(12):1118.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.014]
XU Xiaoting,DAI Chengye,DENG Yifan,et al.Eicosapentaenoic Acid in Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(6):1118.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.014]
[11]曹岩 颜培实.残余胆固醇与动脉粥样硬化性心血管疾病[J].心血管病学进展,2021,(10):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
CAO Yan,YAN Peishi.Remnant Cholesterol And Atherosclerotic?ardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(6):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]